Decoding Cancer's Signals: How Immunopeptidomics is Personalizing Immunotherapy
"Unlock the Future of Personalized Cancer Treatment: Translating Immunopeptidomics into Targeted Immunotherapy for Optimal Patient Selection and Outcomes."
Immunotherapy is changing how we fight cancer, showing remarkable success, especially against tumors with many mutations. This success often relies on neo-antigens, unique markers arising from patient-specific mutations. However, to broaden the reach of immunotherapy to more cancer types and patients with fewer mutations, we need to look beyond neo-antigens to other cancer-related targets.
Mass spectrometry is a powerful tool for directly and impartially discovering and selecting tumor-specific HLA peptides, which can serve as targets for immunotherapy. Gathering these targets into a comprehensive library opens doors for multi-target therapies and speeds up clinical applications. For truly personalized treatment, it's crucial to confirm the presence of these targets on each patient's tumor to ensure both effectiveness and safety.
This article delves into how combining LC-MS with gene expression data helps define mRNA biomarkers. These biomarkers are now used in diagnostic tests like IMA_Detect™ to carefully select patients and personalize target selection within clinical trials (NCT02876510, NCT03247309). We'll explain how HLA peptide presentation translates into gene expression thresholds for companion diagnostics in immunotherapy, considering how peptides correlate to their encoding mRNA.
A Growing Peptide Atlas
A 2025 study assembled a pan-cancer immunopeptidomics atlas from 531 samples spanning 14 cancer types and 29 normal tissues. It identified 389,165 canonical peptides and 70,270 noncanonical peptides, highlighting the scale of naturally presented targets relevant to personalized immunotherapy. Complementary resources such as CAN-IMMUNE integrate mutation data from COSMIC, DepMap/CCLE, and PubMed, while PCI-DB provides immunopeptidomics data from cancerous and healthy samples.
From Tumor Data to Candidate Targets
Immunopeptidomics commonly combines mass spectrometry with genomic or transcriptomic information to identify peptides presented by tumor cells. Candidate targets must then be evaluated for whether they are tumor-associated, naturally presented, and capable of eliciting a useful immune response. Because these measurements and predictions remain technically demanding, results may be constrained by sample quality, incomplete biological coverage, and uncertainty about clinical effectiveness.
A Century of Immune-Based Treatment
The history of cancer immunotherapy extends across more than 100 years, beginning with early observations that immune responses could affect tumors. Later laboratory experiments and clinical applications gradually moved the field toward integration with standard oncology care. Accounts of the field highlight milestones ranging from Coley's Toxins to checkpoint inhibitors and Nobel-winning CAR-T therapy, while also documenting persistent challenges.
Unlocking Personalized Immunotherapy: How Immunopeptidomics Bridges the Gap
The increasing ability to map HLA ligandomes using mass spectrometry is paving the way for new immunotherapies. This research shows how understanding the human immunopeptidome across healthy and cancerous tissues goes beyond just finding targets; it's about validation and application. Quantifying HLA-bound peptides using label-free LC-MS is essential to confirm their correlation with mRNA measured by RNA-Seq.
- HLA Peptide Isolation and Mass Spectrometry: Integrated HLA ligandome - transcriptome analysis was performed for a set of 170 HLA-A02 positive tumor samples from 21 cancer types. Samples were surgically excised after written informed consent, snap-frozen in liquid nitrogen upon extraction and stored at -80°C until HLA precipitation. HLA peptide complexes were isolated by immunoprecipitation using the HLA-A02 specific antibody BB7.2. After ultrafiltration peptide extracts were separated by reversed-phase chromatography.
- RNA Isolation and Sequencing: In parallel to every peptide preparation, total RNA was isolated using TRIzol (Invitrogen, Karlsruhe, Germany) followed by purification with the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. RNA sequencing and expression quantification were performed by CeGaT (Tübingen, Germany). In brief, 1-2 µg total RNA were used as starting material for the library preparation performed according to the Illumina protocol.
- RNA-Seq Data Analysis: Reads were aligned against the human reference genome GRCh38.p1 and annotated with Ensembl 77 (http://www.ensembl.org). Gene expression levels were determined by extraction of read counts per exon using bedtools 2.19.1 [15] and conversion to FPKM values by normalization according to exon length and the number of mapped reads.
Toward Personalized Antigen Selection
A 2025 study reported immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy. Recent reviews also describe next-generation sequencing and machine-learning-based epitope prediction as tools for identifying and prioritizing antigens. In parallel, personalized and autologous nanovaccines are being explored to align delivered immunogens with an individual patient's tumor profile.
Important Translational Barriers
Personalized cancer vaccines remain promising but face significant challenges and limitations before they can transform routine treatment. The cited discussions identify unresolved questions around neoantigen vaccines, mRNA platforms, immune memory, circulating tumor DNA, and clinical readiness. One review also notes that current technology cannot deliver multiple peptides, a limitation that has motivated the development of personalized oncolytic viruses as a potential workaround.
Comparing Vaccine and Discovery Strategies
Personalized cancer vaccines can be organized into mRNA, DNA, peptide, dendritic-cell, and whole-cell approaches. Comparative evaluation of immunopeptidomics-related methods also includes rule-based and machine-learning strategies for personalized antigen discovery and neoantigen vaccine design. One proteomics analysis assessed classifier performance across many peptide-MHC targets using F scores and delta F scores for a representative set of 1,000 randomly selected peptides.
The Future of Cancer Treatment: Precision and Personalization
Mass spectrometry is not only enabling in-depth analysis of the human immunopeptidome, expanding available targets for immunotherapy, but also allowing for the definition of mRNA-based predictive biomarkers. These can be used as qPCR companion diagnostics in clinical studies to identify patient populations most likely to benefit from specific peptide targets, paving the way for personalized peptidomics.
From Discovery to Clinical Translation
Immunopeptidomics now spans basic research, preclinical investigation, and clinical research and applications. Reviews describe its contribution to next-generation cancer vaccine development while emphasizing major translational challenges. Its future clinical value will depend on converting peptide-presentation measurements into reliable treatment decisions and broadly usable immunotherapy designs.
Building More Predictive Therapies
Future work will likely focus on improving the accuracy, speed, and clinical usability of personalized antigen selection. Researchers may combine richer tumor measurements with stronger computational prediction and more flexible vaccine platforms. These directions are promising, but their eventual benefit remains dependent on validation in well-designed clinical studies.
Access and Implementation
The broader adoption of personalized immunotherapy will require coordinated advances in laboratory testing, data analysis, manufacturing, and clinical delivery. Differences in institutional resources and patient access could affect who benefits from increasingly individualized treatments. Standardized workflows and evidence-based evaluation may help address these systemic barriers, although their development will take time.
Personalization in Patient Care
For patients, personalized immunotherapy promises treatment choices informed by the biological features of an individual tumor rather than by broad disease categories alone. Real-world impact will depend not only on identifying relevant peptides but also on making testing, treatment production, and clinical decision-making practical. Patient expectations should therefore be balanced with the uncertainty that accompanies emerging, individualized approaches.
The availability of these biomarkers promises to improve treatment efficacy by implementing precision medicine in cancer immunotherapies. While T cells are more sensitive in recognizing peptide/HLA complexes than current mass spectrometry, the defined thresholds offer a conservative approach. Many patients with lower expression levels could also benefit from treatment.
The suggested threshold is a starting point for early clinical studies that need to be validated and adjusted during clinical development. Combining multiple targets can create target warehouses, enabling active personalization and minimizing the chances of tumor evasion, marking a significant step towards more effective and tailored cancer treatments.